作者
Sanja Đačić,William D. Travis,Jennifer M. Giltnane,Filip Kos,John H. Abel,Stephanie Hilz,Junya Fujimoto,Lynette M. Sholl,J. Ritter,Farah Khalil,Lei Zhu,Amaro Taylor‐Weiner,Murray B. Resnick,Hui Yu,Fred R. Hirsch,Paul A. Bunn,David P. Carbone,Valerie W. Rusch,David J. Kwiatkowski,Bruce E. Johnson,Jay M. Lee,Stephanie Hennek,Ilan Wapinski,Alan Nicholas,Ann Johnson,Katja Schulze,Mark G. Kris,Ignacio I. Wistuba
摘要
Pathologic response (PathR) by histopathologic assessment of resected specimens may be an early clinical end point associated with long-term outcomes with neoadjuvant therapy. Digital pathology may improve the efficiency and precision of PathR assessment. LCMC3 (NCT02927301) evaluated neoadjuvant atezolizumab in patients with resectable NSCLC and reported a 20% major PathR rate.
不配.
含蓄的明雪
苏卿
哎嘿
暮霭沉沉
互助遵法尚德
iNk
吃不饱星球球长
pcr163
彭于彦祖
从容芮
HEIKU
薰硝壤
Henry
tuanheqi
Yziii
加湿器
Loooong
乐乐乐乐乐乐
大有阳光
皖公网安备34019202002308
